FDA urgently authorizes new crown special drugs to eliminate virus in 3 days, including Omicron

Recently, a study by Merck in the United States showed that taking the new anti-new coronavirus drug Molnupiravir for 3 days can eliminate the new coronavirus, and it is effective against the original strain of SARS-CoV-2, Delta and Omicron, while receiving placebo Participants treated with the drug took 5 days or more to reach this goal
.

The research, to be presented at this year's European Congress of Clinical Microbiology and Infectious Diseases, was conducted by Dr.
Julie Strizki of Merck & Co.
and colleagues
.

 Figure 1 Screenshot of related information (Source: [1]) Molnupiravir is an oral antiviral prodrug with broad activity against coronaviruses, including SARS-CoV-2 and its variants of concern
.

This randomized, placebo-controlled, double-blind, Phase 2/3 MOVe-OUT trial confirmed that Molnupiravir, started within 5 days of symptom onset, in non-hospitalized adult patients with mild/moderate COVID-19 at risk of developing severe disease, Its effect is better than a placebo
.

The drug has been granted emergency use authorization by the US FDA and is authorized for use in the UK, Australia, Japan and 12 other countries and territories
.

 In the study, the researchers analyzed changes in viral load in 188 people infected with the new coronavirus, dividing the patients into two groups, one of 92 people taking Molnupiravir and the other 96 people taking a placebo
.

Viral loads in patients were determined from days 1 (baseline), 3, 5 (end of treatment), 10, 15, and 29 using PCR assays
.

 The results showed that on day 3 of treatment, 92 subjects with infectious virus at baseline had no detectable infectious SARS-CoV-2 after treatment with Molnupiravir
.

In comparison, 21.
8% of the infectious SARS-CoV-2 remained in the patients who received the placebo
.

On day 5, the virus detection rate in the Molnupiravir group was 0%, compared with 2.
2% in the placebo group
.

 Dr Strizki said: "This analysis of the final virological outcome data from MOVe-OUT confirms previous observations that molnupiravir 800 mg twice daily for 5 days resulted in a rapid reduction of the virus compared to placebo.
RNA, rapid elimination of infectious viruses"
.

In addition, the study confirmed that Molnupiravir can help infected people quickly clear the virus from the body compared to a placebo and supports the main finding of MOVe-OUT that Molnupiravir reduces the risk of developing severe disease in this high-risk group
.

Written by | Mu Zijiu Typesetting | Mu Zijiu End Reference: [1] https://